<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>JCAD &#187; Anti-tumor Necrosis Factor</title>
	<atom:link href="http://www.jcadonline.com/category/areas-of-interest/anti-tumor-necrosis-factor/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.jcadonline.com</link>
	<description>The Journal of Clinical and Aesthetic Dermatology (JCAD)</description>
	<lastBuildDate>Thu, 19 Jan 2012 16:38:25 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Is There a Potential Role for Anti-tumor Necrosis Factor Therapy in Patients with Human Immunodeficiency Virus?</title>
		<link>http://www.jcadonline.com/is-there-a-potential-role-for-anti-tumor-necrosis-factor-therapy-in-patients-with-human-immunodeficiency-virus/</link>
		<comments>http://www.jcadonline.com/is-there-a-potential-role-for-anti-tumor-necrosis-factor-therapy-in-patients-with-human-immunodeficiency-virus/#comments</comments>
		<pubDate>Fri, 17 Apr 2009 13:34:03 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[04-2009 (April 2009)]]></category>
		<category><![CDATA[Anti-tumor Necrosis Factor]]></category>
		<category><![CDATA[Literature Review]]></category>
		<category><![CDATA["anti tumor necrosis factor medications"]]></category>
		<category><![CDATA[# tnf alpha inhibitors in the treatment of dermatitis and psoriatic]]></category>
		<category><![CDATA[aad 2011 jason emer]]></category>
		<category><![CDATA[acitretin basal cell carcinoma jason emer]]></category>
		<category><![CDATA[acitretin prednisone]]></category>
		<category><![CDATA[alpha 420 al]]></category>
		<category><![CDATA[anti tnf alpha and hiv]]></category>
		<category><![CDATA[anti tnf alpha psoriasis treatment contraindication hepatitis b]]></category>
		<category><![CDATA[anti tnf alpha therapy in patients with hiv]]></category>
		<category><![CDATA[anti tnf atopic dermatitis]]></category>
		<category><![CDATA[anti tnf supplements for psoriasis]]></category>
		<category><![CDATA[anti tumor necrosis factors medications and dementia]]></category>
		<category><![CDATA[anti-tumor nuclear factor treatment]]></category>
		<category><![CDATA[aphous ulcers caused by anti-tnfs]]></category>
		<category><![CDATA[aphthous ulcers caused by anti-tnfs]]></category>
		<category><![CDATA[are anti-tnf alpha inhibitors safe in hiv]]></category>
		<category><![CDATA[atopiclair and elevated liver enzymes]]></category>
		<category><![CDATA[biological agent syndromes]]></category>
		<category><![CDATA[biological agents table]]></category>
		<category><![CDATA[effect of anti tnf drugs to hiv positive persons]]></category>
		<category><![CDATA[effect of tnf alpha in fibrosis in hepatitis c]]></category>
		<category><![CDATA[follow up tb treated before starting anti-tumor necrosis factors]]></category>
		<category><![CDATA[hiv-associated psoriasis]]></category>
		<category><![CDATA[hiv-positive patients differ from hiv-negative patients in indications for and type of uv therapy used.]]></category>
		<category><![CDATA[indication of tumor necrosis inhibitor therapy]]></category>
		<category><![CDATA[is enbrel used in hiv infected patients]]></category>
		<category><![CDATA[is psoriatic arthritis an indication for haart]]></category>
		<category><![CDATA[journal article on tnf alpha inhibitor in 2011 and 2010]]></category>
		<category><![CDATA[latent tb concurrent immunosuppressives]]></category>
		<category><![CDATA[letter to the editor etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis c virus infection: a phase 2 randomized, double-blind, placebo-controlled ]]></category>
		<category><![CDATA[lmp-420]]></category>
		<category><![CDATA[lmp-420 and "anti-tnf"]]></category>
		<category><![CDATA[lmp-420 and "tnf agent"]]></category>
		<category><![CDATA[lmp-420 drug]]></category>
		<category><![CDATA[lmp420 tuberculosis]]></category>
		<category><![CDATA[minocycline]]></category>
		<category><![CDATA[moela clear serum dermato]]></category>
		<category><![CDATA[paradoxical adverse events tnf alpha inhibitors]]></category>
		<category><![CDATA[paradoxical flare of psorisis after biologic therapy]]></category>
		<category><![CDATA[psoriasis and aphthous ulcers]]></category>
		<category><![CDATA[psoriasis and hiv etanercept]]></category>
		<category><![CDATA[psoriasis biologics tnf hiv cd4]]></category>
		<category><![CDATA[psoriasis?interleukin]]></category>
		<category><![CDATA[psoriatic arthritis hiv undetectable]]></category>
		<category><![CDATA[research article on tnf alpha inhibitor]]></category>
		<category><![CDATA[research article on tnf alpha inhibitor in 2011 and 2010]]></category>
		<category><![CDATA[rheumatoid arthritis biological agent]]></category>
		<category><![CDATA[role of anti tnf in treatment of psoriasis]]></category>
		<category><![CDATA[safest anti tumor necrosis factor]]></category>
		<category><![CDATA[seroconversion tuberculosis on enbrel]]></category>
		<category><![CDATA[taking adalimumab with high liver enzymes & hep-c]]></category>
		<category><![CDATA[ting pt, koo jy. use of etanercept in human immunodeficiency]]></category>
		<category><![CDATA[tnf alpha concentration psoriasis cachexia]]></category>
		<category><![CDATA[tnf alpha inhibitor increased liver enzymes]]></category>
		<category><![CDATA[tnf alpha inhibitors package insert]]></category>
		<category><![CDATA[tnf alpha inhibitors side effects, liver]]></category>
		<category><![CDATA[tnf antagonists hiv viral load]]></category>
		<category><![CDATA[tnf inhibitor viral replication]]></category>
		<category><![CDATA[tnf inhibitors psoriasis online dermatology]]></category>
		<category><![CDATA[tnf inhibitors therapeutic guidelines]]></category>
		<category><![CDATA[tnf paradoxical psoriasis]]></category>
		<category><![CDATA[tnf-alpha inhibitor, paradoxical exaceration of psoriasis]]></category>
		<category><![CDATA[tnf-alpha level and serum and psoriasis]]></category>
		<category><![CDATA[uptodate literature review on the role of nitric oxide on hiv infection]]></category>
		<category><![CDATA[uses of anti tnf alpha in hiv]]></category>
		<category><![CDATA[what does exaceration]]></category>

		<guid isPermaLink="false">http://www.jcadonline.com/?p=1214</guid>
		<description><![CDATA[Jason J. Emer, MD; The Mount Sinai School of Medicine, Department of Dermatology, New York, New York Abstract Anti-tumor necrosis factor therapy has shown remarkable safety and efficacy in the treatment of many autoimmune and inflammatory disorders, although limited published data exists regarding these treatments in patients with concomitant human immunodeficiency virus and/or acquired immune [...]]]></description>
		<wfw:commentRss>http://www.jcadonline.com/is-there-a-potential-role-for-anti-tumor-necrosis-factor-therapy-in-patients-with-human-immunodeficiency-virus/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

